Moderna Reports 94% Effectiveness in COVID-19 Vaccine Trial
Moderna reveals its experimental COVID-19 vaccine demonstrates a 94.1% effectiveness rate at preventing illness. The promising results bring a second viable vaccine closer to widespread public distribution.
Moderna releases impressive data showing its COVID-19 vaccine is 94.1% effective at preventing symptomatic illness. The results come from a large-scale clinical trial involving 30,000 participants, confirming that a second highly effective vaccine is on the horizon.
The biotech company reports the vaccine prevents all severe cases of the disease among trial volunteers. This milestone matches the high efficacy rates previously reported by Pfizer and BioNTech, reinforcing global hopes for ending the pandemic.
Moderna plans to apply for emergency use authorization from the FDA as it continues gathering safety data. Unlike the Pfizer vaccine, Moderna's candidate does not require ultra-cold storage, which simplifies distribution logistics significantly.